US 12,337,004 B2
Coumarin-modified androgens for the treatment of prostate cancer
James L. Mohler, Buffalo, NY (US); Michael V. Fiandalo, Buffalo, NY (US); David Watt, Lexington, KY (US); and Vitaliy Sviripa, Frederick, MD (US)
Assigned to Health Research, Inc., Buffalo, NY (US); and University of Kentucky Research Foundation, Lexington, KY (US)
Appl. No. 17/606,998
Filed by Health Research, Inc., Buffalo, NY (US); and University of Kentucky Research Foundation, Lexington, KY (US)
PCT Filed Apr. 27, 2020, PCT No. PCT/US2020/030147
§ 371(c)(1), (2) Date Oct. 27, 2021,
PCT Pub. No. WO2020/223174, PCT Pub. Date Nov. 5, 2020.
Claims priority of provisional application 62/890,292, filed on Aug. 22, 2019.
Claims priority of provisional application 62/844,062, filed on May 6, 2019.
Claims priority of provisional application 62/844,073, filed on May 6, 2019.
Claims priority of provisional application 62/839,676, filed on Apr. 27, 2019.
Prior Publication US 2022/0218722 A1, Jul. 14, 2022
Int. Cl. A61K 31/585 (2006.01); A61K 31/167 (2006.01); A61K 31/277 (2006.01); A61K 31/4155 (2006.01); A61K 31/4166 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/58 (2006.01); A61K 49/00 (2006.01); C07J 43/00 (2006.01)
CPC A61K 31/585 (2013.01) [A61K 31/167 (2013.01); A61K 31/277 (2013.01); A61K 31/4155 (2013.01); A61K 31/4166 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/58 (2013.01); A61K 49/0002 (2013.01); C07J 43/003 (2013.01); C07J 43/006 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A compound having the following structure:

OG Complex Work Unit Chemistry
wherein
R1 is hydrogen or an alkyl group;
L1 is a linking group, L2 is optional and is a linking group,
Z is an end group comprising (a) a substituted or unsubstituted coumarin group or
(b)

OG Complex Work Unit Chemistry
or a substituted variant thereof, and R2 is an alkyl group or hydrogen.